The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population

A pilot study

Dushyantha T Jayaweera, E. Scerpella, M. Robinson, R. Rode, Rafael E Campo, Allan E Rodriguez, D. Asthana, T. Tanner, Michael A Kolber

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We evaluated the safety and efficacy of indinavir 400 mg and ritonavir 400 mg twice daily (RIT/IND 400/400) in HIV-1-infected individuals, using an open label, proof of concept study. All patients received indinavir 400 mg and ritonavir 400 mg twice daily. Patients were followed up to 48 weeks. Nineteen subjects were enrolled, 11 (58%) men and eight (42%) women. The majority were American Black (nine; 47%) or Haitian (eight; 42%). The median baseline plasma HIV-1 viral load (VL) was 5.13 log10 copies/mL and the median CD4 cell count was 112 cells/mm3. The proportion of compliant patients with VL <400 copies/mL at week 24 was 60% compared with 0% for non-compliant patients (P = 0.011 [intent-to-treat] or P = 0.085 [on-treatment]). VL at week 4 predicted week 24 VL response. Compliant patients had a median average CD4 cell count increase of 83.2 cells/mm3 compared with 42.0 cells/mm3 for non-compliant patients (P = 0.010). The median average changes in triglycerides and cholesterol were significantly higher in compliant patients. This is a potent, safe combination for the treatment of HIV-1. VL at week 4 is predictive of viral outcome at week 24. Fasting serum cholesterol and triglycerides were significantly elevated during the study.

Original languageEnglish
Pages (from-to)732-736
Number of pages5
JournalInternational Journal of STD and AIDS
Volume14
Issue number11
DOIs
StatePublished - Nov 1 2003

Fingerprint

Indinavir
Ritonavir
HIV-1
Viral Load
Safety
Population
CD4 Lymphocyte Count
Triglycerides
Cholesterol
Fasting
Therapeutics
Serum

Keywords

  • Efficacy
  • Indinavir
  • Ritonavir
  • Safety

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this

The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population : A pilot study. / Jayaweera, Dushyantha T; Scerpella, E.; Robinson, M.; Rode, R.; Campo, Rafael E; Rodriguez, Allan E; Asthana, D.; Tanner, T.; Kolber, Michael A.

In: International Journal of STD and AIDS, Vol. 14, No. 11, 01.11.2003, p. 732-736.

Research output: Contribution to journalArticle

@article{1f87e986ff2c401ba167bd4cfc8fd7ab,
title = "The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population: A pilot study",
abstract = "We evaluated the safety and efficacy of indinavir 400 mg and ritonavir 400 mg twice daily (RIT/IND 400/400) in HIV-1-infected individuals, using an open label, proof of concept study. All patients received indinavir 400 mg and ritonavir 400 mg twice daily. Patients were followed up to 48 weeks. Nineteen subjects were enrolled, 11 (58{\%}) men and eight (42{\%}) women. The majority were American Black (nine; 47{\%}) or Haitian (eight; 42{\%}). The median baseline plasma HIV-1 viral load (VL) was 5.13 log10 copies/mL and the median CD4 cell count was 112 cells/mm3. The proportion of compliant patients with VL <400 copies/mL at week 24 was 60{\%} compared with 0{\%} for non-compliant patients (P = 0.011 [intent-to-treat] or P = 0.085 [on-treatment]). VL at week 4 predicted week 24 VL response. Compliant patients had a median average CD4 cell count increase of 83.2 cells/mm3 compared with 42.0 cells/mm3 for non-compliant patients (P = 0.010). The median average changes in triglycerides and cholesterol were significantly higher in compliant patients. This is a potent, safe combination for the treatment of HIV-1. VL at week 4 is predictive of viral outcome at week 24. Fasting serum cholesterol and triglycerides were significantly elevated during the study.",
keywords = "Efficacy, Indinavir, Ritonavir, Safety",
author = "Jayaweera, {Dushyantha T} and E. Scerpella and M. Robinson and R. Rode and Campo, {Rafael E} and Rodriguez, {Allan E} and D. Asthana and T. Tanner and Kolber, {Michael A}",
year = "2003",
month = "11",
day = "1",
doi = "10.1258/09564620360719750",
language = "English",
volume = "14",
pages = "732--736",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "11",

}

TY - JOUR

T1 - The safety and efficacy of indinavir and ritonavir (400/400 mg BID) in HIV-1-infected individuals from an inner-city minority population

T2 - A pilot study

AU - Jayaweera, Dushyantha T

AU - Scerpella, E.

AU - Robinson, M.

AU - Rode, R.

AU - Campo, Rafael E

AU - Rodriguez, Allan E

AU - Asthana, D.

AU - Tanner, T.

AU - Kolber, Michael A

PY - 2003/11/1

Y1 - 2003/11/1

N2 - We evaluated the safety and efficacy of indinavir 400 mg and ritonavir 400 mg twice daily (RIT/IND 400/400) in HIV-1-infected individuals, using an open label, proof of concept study. All patients received indinavir 400 mg and ritonavir 400 mg twice daily. Patients were followed up to 48 weeks. Nineteen subjects were enrolled, 11 (58%) men and eight (42%) women. The majority were American Black (nine; 47%) or Haitian (eight; 42%). The median baseline plasma HIV-1 viral load (VL) was 5.13 log10 copies/mL and the median CD4 cell count was 112 cells/mm3. The proportion of compliant patients with VL <400 copies/mL at week 24 was 60% compared with 0% for non-compliant patients (P = 0.011 [intent-to-treat] or P = 0.085 [on-treatment]). VL at week 4 predicted week 24 VL response. Compliant patients had a median average CD4 cell count increase of 83.2 cells/mm3 compared with 42.0 cells/mm3 for non-compliant patients (P = 0.010). The median average changes in triglycerides and cholesterol were significantly higher in compliant patients. This is a potent, safe combination for the treatment of HIV-1. VL at week 4 is predictive of viral outcome at week 24. Fasting serum cholesterol and triglycerides were significantly elevated during the study.

AB - We evaluated the safety and efficacy of indinavir 400 mg and ritonavir 400 mg twice daily (RIT/IND 400/400) in HIV-1-infected individuals, using an open label, proof of concept study. All patients received indinavir 400 mg and ritonavir 400 mg twice daily. Patients were followed up to 48 weeks. Nineteen subjects were enrolled, 11 (58%) men and eight (42%) women. The majority were American Black (nine; 47%) or Haitian (eight; 42%). The median baseline plasma HIV-1 viral load (VL) was 5.13 log10 copies/mL and the median CD4 cell count was 112 cells/mm3. The proportion of compliant patients with VL <400 copies/mL at week 24 was 60% compared with 0% for non-compliant patients (P = 0.011 [intent-to-treat] or P = 0.085 [on-treatment]). VL at week 4 predicted week 24 VL response. Compliant patients had a median average CD4 cell count increase of 83.2 cells/mm3 compared with 42.0 cells/mm3 for non-compliant patients (P = 0.010). The median average changes in triglycerides and cholesterol were significantly higher in compliant patients. This is a potent, safe combination for the treatment of HIV-1. VL at week 4 is predictive of viral outcome at week 24. Fasting serum cholesterol and triglycerides were significantly elevated during the study.

KW - Efficacy

KW - Indinavir

KW - Ritonavir

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0242690233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242690233&partnerID=8YFLogxK

U2 - 10.1258/09564620360719750

DO - 10.1258/09564620360719750

M3 - Article

VL - 14

SP - 732

EP - 736

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 11

ER -